Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

The program will provide direct shipping to patients across all 50 states and Puerto Rico, offering an additional, simplified option for accessing Eliquis and full transparency into the associated ...

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients ...

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac P ...

Among older adults with atrial fibrillation, apixaban was linked to lower rates of adverse events across all frailty levels compared with warfarin, a retrospective observational study showed. In ...

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is already ...

A lifetime on the newer agent was cost-effective within US "reasonable norms" but didn't cut overall costs much by improving outcomes, mostly because apixaban itself is far costlier than warfarin.

In patients with a-fib and valvular heart disease, treatment with apixaban was associated with a lower risk of stroke or systemic embolism and bleeding vs rivaroxaban.